44 contacts, two conflicting itineraries: Abuja’s unresolved Ebola investigation

Forty-four people were identified as contacts of the woman diagnosed with Ebola in Abuja. That number describes the reach of an investigation, not a count of infections: each possible exposure needs checking, and each person’s outcome matters. Yet investigators still lack a settled account of where the patient travelled before becoming ill. She reportedly denies the Congo visit that Ugandan officials described. ^{32 1}

On October 21, HeyDay News reported Nigeria’s laboratory-confirmed October 20 diagnosis and the identification of 44 contacts. The new development is not another Nigerian case. It is a sharper conflict over the patient’s itinerary, alongside an inconsistent return-date chronology and an announced continental response. Kenya’s nine confirmed cases were already documented by October 20, rather than representing a fresh expansion on October 22. ^{5 1 49 65}

The Abuja patient is a Ugandan national who lives in the Nigerian capital with her husband, a Swiss diplomat, according to the October 22 account published by The Seattle Times. Nigeria’s October 20 announcement said she was in isolation and receiving care after several days at a private hospital. WHO identified her infection as imported Bundibugyo Ebola disease. No later clinical update establishes whether she has improved, deteriorated or recovered. ^{1 5 33}

The earlier itinerary described a business trip to eastern Democratic Republic of the Congo, followed by passage through Uganda on the way home. Nairametrics reported Uganda’s position on October 21; The Seattle Times subsequently reported the Ugandan Health Ministry’s qualification: “Travel through Uganda does not establish that infection occurred here.” That distinction remains important. A departure airport is not an infection site. ^{67 1}

But Africa CDC director-general Jean Kaseya gave The Seattle Times a different account: the woman told investigators she had not visited Congo at all and had spent two weeks holidaying in Kampala. This is no longer simply a question of distinguishing a transit stop from an earlier destination. The accounts disagree over whether the Congo trip happened. Neither establishes where she became infected. ¹

Our October 21 report treated departure from Uganda and an earlier Congo visit as potentially compatible descriptions of one journey. The reported denial now prevents that reconciliation. Investigators need a complete, dated itinerary and evidence of an actual exposure—not a choice between two plausible-looking routes.

The arrival date also needs correction from certainty to dispute. We previously reported October 5, attributed to a Nigerian disease-control official. The Seattle Times’ October 22 account repeats that date but also reports WHO’s Africa office placing symptom onset on October 7, four days after her return. That implies October 3. Both chronologies place the start of illness on October 7; they cannot both supply the same return date. Nigeria’s original announcement said only that she had recently arrived from Uganda. ^{1 5}

She sought care for malaria-like symptoms on October 11, but doctors did not suspect Ebola for more than a week. Laboratory confirmation followed on October 20—nine days after that hospital encounter. Accounts describe October 11 as either presentation or admission, leaving the full sequence of care unclear. What is clear is that tracing must examine the period before diagnosis, including healthcare and other encounters, without assuming any particular encounter transmitted infection. ^{1 8}

Health Minister Muhammad Ali Pate’s October 20 announcement identified 44 contacts and a plan for isolation lasting at least three weeks, as reported by Premium Times. The newer Seattle Times account says at least 44, including many healthcare workers, were being monitored. That wording does not establish a verified higher total, that everybody was reached, or that everybody completed monitoring. Each person’s monitoring period depends on their own exposure date. ^{32 1}

No subsequent confirmed infection among those contacts has been established in the available reporting. Nor has an all-clear. Missing outcomes cannot honestly be turned into either evidence of spread or proof of containment. The hospital’s name, the patient’s treatment and prognosis, the specimen-collection date, diagnostic assay details and case-specific sequencing findings also remain unestablished. October 20 is the confirmation date, not a demonstrated specimen-collection date. ^{5 33 1}

Kenya offers a concrete warning about what can follow an imported infection, but its chronology should not be reset by a later headline. WHO was notified of the first laboratory-confirmed case on October 5. The patient had lived in Congo, become ill and received care there, then travelled through Uganda to Kenya. The patient was diagnosed on October 5 and died that night. ^{64 60 1}

The Kenyan total reached three by October 16. The second and third patients were close family members, with the third found in quarantine. Four cases reported October 17 brought the total to seven: three healthcare workers who treated the first patient and a close male relative. An eighth followed on October 18 and a ninth on October 20. Our earlier Kenya coverage had already carried that nine-case total; BBC reporting dated October 20 also documented it. ^{62 65}

The eight additional patients are described as contacts of the first patient. That supports an epidemiologically linked Kenyan cluster, not a demonstrated transmission chain connecting it to the Abuja woman. Nor does the travellers’ passage through Uganda prove renewed transmission there. Uganda’s earlier outbreak, reported as 20 cases and two deaths, was declared ended in August. Those are historical totals, not evidence of current infections. ¹

An October 22 Kenya News Agency report described 14 samples collected from suspected cases without supplying their results. Those samples cannot be added to the nine confirmed infections. A sample count is not necessarily a count of people, and neither is a confirmed-case tally. ⁵⁹

Congo remains the centre of the crisis, but its totals need dates attached. ECDC’s October 20 update gave 9,552 confirmed cases and 4,602 deaths using data through October 18. An October 23 EconoTimes account gave 9,637 confirmed cases and 4,646 deaths by October 19. The later publication date does not make that an October 23 surveillance count, and the successive cutoffs are not inherently contradictory. ^{53 57}

The Seattle Times reported more than 9,700 confirmed cases and more than 4,600 deaths on October 22. An archive assigns 9,704 cases and 4,687 deaths to Congo’s situation report dated October 20 and published October 21. However, the accessible original excerpt does not establish that cumulative pair or that all 9,704 were confirmed. The higher figure should therefore not be treated as a fully verified, current confirmed-case total. ^{1 51 52}

Our October 20 coverage had already reported expansion into Nord-Ubangi, Congo’s eighth affected province. The broader containment problem extends beyond provincial or national boundaries: The Seattle Times reports that about 70% of new Congolese cases occur in the community, suggesting infections may be escaping early detection. The report supplies no observation window or denominator for that proportion. ¹

The same account describes Bundibugyo vaccine trials underway, with doses not expected for many more months. It reports that children under five account for nearly one in four cases and one in three deaths, while being excluded from the trials discussed. That is a serious protection gap, though not evidence of every trial’s eligibility rules or a firm vaccine delivery date. ¹

Africa CDC announced on October 21 that African health ministers would meet virtually on Wednesday, October 28. Nigeria brings experience from containing an imported Ebola cluster in 2014, drawing partly on its polio-response infrastructure. That is useful capacity, not a guarantee. The immediate test remains whether investigators can establish the Abuja patient’s exposure, reach everyone who needs monitoring and determine whether the infection stopped with her. ^{49 1}